All In Biotech

Drug Trial Radar · NCT05029609

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS

Last checked: Nov 20, 2026Latest source record: Mar 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 2021

Primary completion

Nov 2022

Study completion Dec 2022

Sponsor

Lead sponsor
Tiziana Life Sciences LTDIndustry
Sponsor type
Industry
First posted
Aug 31, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses for 14 consecutive days.

Conditions

  • Primary Progressive Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis
  • Multiple Sclerosis

Interventions

  • Intranasal Foralumab SolutionDrug

    The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.

  • PlaceboDrug

    The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish the safety of intranasal foralumab in non-active primary and secondary progressive MS in escalating doses for 14 consecutive daysTime frame: 14 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.